Homepage
Catalog of Screening Compounds Screening Libraries Focused and Target Libraries Active Reference Sets Diversity Libraries
Screening Compounds Building blocks
Drug Discovery Services Custom Chemistry Medicinal chemistry In silico Drug Design (CADD) Discovery Biology Animal Models Toxicology and Safety ADME, DMPK Chemistry, Manufacturing and Controls
Company News & Media Contact us For suppliers Trends in discovery compounds
Homepage > Company > Media > Pharma News

Pharma News

Celgene signs deal with BeiGene for tumor cancer treatment
Celgene signs deal with BeiGene for tumor cancer treatment
Celgene Corp (CELG.
FDA puts on hold Keytruda studies
FDA puts on hold Keytruda studies
US regulators have placed on clinical hold three studies testing the immunotherapy Keytruda in combination with other therapies for multiple myeloma because of patient deaths.
Genentech’s Emicizumab Demonstrates Positive Results in Late-Stage Studies in Hemophilia A with Inhibitors
Genentech’s Emicizumab Demonstrates Positive Results in Late-Stage Studies in Hemophilia A with Inhibitors
SOUTH SAN FRANCISCO, Calif.
Gemphire's cholesterol drug shows promise in Phase 2
Gemphire's cholesterol drug shows promise in Phase 2
Gemphire Therapeutics expects new topline, Phase 2 data will usher its drug aimed at cutting down bad cholesterol into late-stage testing.
Success for Merck’s anacetrapib
Success for Merck’s anacetrapib
The CETP inhibitor surprises with positive Phase III results.
Philips to buy medical device maker Spectranetics for 1.9 billion euros
Philips to buy medical device maker Spectranetics for 1.9 billion euros
Dutch healthcare company Philips (PHG.
FDA approves new indication for Amgen’s Vectibix
FDA approves new indication for Amgen’s Vectibix
SILVER SPRING, Md.
Japan’s First DPP-4 Inhibitor / SGLT2 Inhibitor Combination Drug Application approved in Japan for CANALIA Combination Tablets, a type 2 diabetes mellitus treatment agent
Japan’s First DPP-4 Inhibitor / SGLT2 Inhibitor Combination Drug Application approved in Japan for CANALIA Combination Tablets, a type 2 diabetes mellitus treatment agent
Osaka and Tokyo, Japan (July 3, 2017) - Mitsubishi Tanabe Pharma Corporation (hereafter Mitsubishi Tanabe Pharma; Head Office.
UK ministers attempt to provide certainty on EMA relations post-Brexit
UK ministers attempt to provide certainty on EMA relations post-Brexit
After a year of uncertainty, a letter written by two senior government ministers has finally sought to clear up what the UK’s relationship with the European Medicines Agency (EMA) might look...
STADA Arzneimittel AG appoints new Chief Executive Officer and Chief Financial Officer – incumbents step down from their positions
STADA Arzneimittel AG appoints new Chief Executive Officer and Chief Financial Officer – incumbents step down from their positions
Bad Vilbel, July 4, 2017 – The Supervisory Board of STADA Arzneimittel AG has appointed Engelbert Coster Tjeenk Willink (56) as Chief Executive Officer with immediate effect.
GSK has secured access to Exscientia’s artificial intelligence (AI)-driven drug discovery platform
GSK has secured access to Exscientia’s artificial intelligence (AI)-driven drug discovery platform
GSK said it will nominate up to 10 targets for small molecule discovery by Exscienta’s platform, which identifies mono- and bispecific small molecule drugs by phenotypic and high content screening a...
New hard-to-treat leukemia drug Besponsa approved in the Europe
New hard-to-treat leukemia drug Besponsa approved in the Europe
Following a positive recommendation in April from the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP), the European Commission has approved US pharma giant ...
Catalog of Screening Compounds Screening Libraries Screening Compounds Building blocks
Drug Discovery Services News & Media Contact us
Payment systems
Policies & Terms     ©2023 ChemDiv     ChemistryOnDemand